Industry Overview

Indian pharmaceutical contract manufacturing market was valued at $17.4 billion in 2025 and is projected to reach $48.5 billion by 2035, growing at a CAGR of 9.8% during the forecast period (2026-2035). The market is booming, driven by its cost-effectiveness, skilled workforce, strong API base, and government support, positioning India as a global pharma hub, especially for generics, vaccines, and APIs, with growth fueled by rising global demand, R&D focus, and the need for flexible supply chains. Key growth factors include a large pool of scientific talent, strong regulatory compliance (US FDA, EMA), integrated ecosystem (APIs to logistics), and Make in India initiatives, while challenges involve rising intermediate costs from China.

Market Dynamics

Rising prevalence of respiratory diseases (asthma, COPD, chronic conditions)

One of the strongest drivers for the global respiratory drug market is the steadily increasing burden of respiratory diseases globally, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), and other chronic respiratory ailments. Factors contributing to this rise include deteriorating air quality (pollution, allergens), smoking and second?hand smoke exposure, urbanization, changing lifestyles, occupational hazards, and aging. As more people are diagnosed with respiratory conditions (including newly emerging cases and exacerbations among existing patients), demand for effective respiratory drug inhalers, corticosteroids, bronchodilators, and biologics rises correspondingly. Because these conditions are often chronic, long-term maintenance therapy is required, which sustains demand over time rather than creating only one-time sales. This persistent and growing patient pool underpins long-term growth for drug manufacturers and supports consistent expansion of the respiratory drug market.

Technological and formulation innovations in drug delivery & therapies

Advances in drug development, formulation, and especially delivery technologies have significantly boosted the market. Newer inhalation devices such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), nebulizers, and increasingly smart inhalers (with sensors, dosage tracking, reminders, and digital adherence support) have improved drug delivery efficiency, patient convenience, and adherence, all of which increase uptake and treatment success. Additionally, the expanding use of more advanced therapies, including long-acting bronchodilators, combination therapies (combining inhaled corticosteroids, long-acting beta-agonists, or muscarinic antagonists), and biologics/targeted therapies for severe or difficult-to-treat respiratory conditions, is broadening the therapeutic repertoire. Such innovations not only improve outcomes for patients but also encourage treatment even in more severe or previously hard-to-treat cases. That expands the market beyond simple maintenance therapy to more complex, higher-value treatments.

Aging population, growing healthcare access & rising awareness globally

Demographic changes, especially a growing proportion of older adults globally, contribute to rising demand for respiratory drugs. Older populations are more prone to chronic respiratory diseases (weakened lung function, comorbidities, and age?related susceptibility), thus increasing the incidence and prevalence of conditions like COPD, asthma exacerbations, and related complications. Simultaneously, improved healthcare infrastructure, rising healthcare expenditure, better diagnosis rates, and increased awareness about respiratory conditions are enabling more patients to be diagnosed and treated. In many regions, including emerging markets, growing access to healthcare facilities, medications, reimbursement or insurance, and public-health initiatives helps expand the reach of respiratory drugs. This expanded access, combined with awareness campaigns, leads to higher treatment rates and more consistent demand for respiratory medications globally.

Market Segmentation

• Based on the category, the market is segmented into human-based drugs and animal-based drugs.
• Based on the type, the market is segmented into sterile manufacturing and non-sterile manufacturing.
• Based on the product, the market is segmented into over-the-counter (OTC) drugs, active pharmaceutical ingredients (API), finished dosage formulation, and others.

Finished Dosage Formulation Segment to Lead the Market with the Largest Share

Pharmaceutical contract manufacturing market, finished dosage formulation emerges as the largest and leading segment. This segment dominates due to the increasing demand for ready-to-use pharmaceutical products that ensure patient compliance, convenience, and safety. Finished dosage formulations, including tablets, capsules, injectables, and syrups, are critical for both domestic consumption and export markets, driving growth for contract manufacturers. The rising prevalence of chronic diseases, growing healthcare infrastructure, and the preference of pharmaceutical companies to outsource production for cost efficiency and faster market access further bolster the prominence of this segment. Additionally, the segment benefits from stringent quality standards and regulatory compliance, which larger contract manufacturers are better equipped to handle, solidifying its leadership position in the market. 

Human-Based Drugs: Key Segment in Market Growth

Human-based drugs segment has emerged as the key driver of market growth. This segment dominates due to the rising prevalence of chronic diseases, increasing demand for specialty medicines, and the expansion of biologics and biosimilars in India. Human-based drugs, which include vaccines, monoclonal antibodies, recombinant proteins, and other therapeutics, are witnessing robust adoption across hospitals, clinics, and specialty care centers. The increasing healthcare expenditure in India, coupled with favorable government policies supporting pharmaceutical manufacturing and exports, has further bolstered the growth of this segment.

Additionally, the surge in research and development activities by global pharmaceutical companies in India has led to higher outsourcing of human drug manufacturing to local contract manufacturing organizations (CMOs). This trend is amplified by the country’s cost-effective labor and regulatory framework, which makes India a preferred destination for human-based drug production. While animal-based drugs and non-sterile manufacturing segments are growing steadily, the demand for advanced biologics, vaccines, and complex human therapeutics ensures that Human-Based Drugs remain the primary growth segment in the Indian pharmaceutical contract manufacturing market over the forecast period. This segment’s contribution is critical in shaping the overall market trajectory and attracting investment from both domestic and international pharmaceutical players.

Market Players Outlook

The major companies operating in the global Indian pharmaceutical contract manufacturing market include Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In October 2025, Eli Lilly planned to invest over $1 billion in contract manufacturing in India over the coming years to enhance access to its medicines and bolster manufacturing capabilities. This investment includes establishing a new Manufacturing & Quality hub in Hyderabad, which will oversee the contract manufacturing network. Recruitment for various technical roles will start immediately. Since 2020, Lilly has invested over $55 billion globally to build and expand facilities, focusing on developing new treatments for diabetes, obesity, Alzheimer's disease, cancer, and autoimmune conditions.

The Report Covers

• Market value data analysis of 2024 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the Indian pharmaceutical contract manufacturing market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.